Katherine Cabral

Katherine Cabral

Education

  • PGY-2, Cardiology Specialty Residency, Boston Medical Center, Boston MA
  • PGY-1, Pharmacy Practice Residency, Boston Medical Center, Boston MA
  • PharmD, Northeastern University, Bouve College of Health Sciences, Boston MA

Courses Taught at ACPHS

  • PTPM Cardiovascular module
  • Advanced Pharmacy Practice Experience – Cardiology
  • Residency Prep Elective
  • Integrated Problem Solving (IPS) Workshop 4

PGY2 Residency Program Director

Dr. Cabral is the Program Director for the PGY2 Residency in Cardiology Pharmacy.

Practice Site

Capital Cardiology Associates

Research Interests

  • Antithrombotic therapies
  • Heart Failure therapy
  • Role of a clinical pharmacist in ambulatory cardiology care
  • Acute coronary syndromes pharmacotherapy
  • Heparin induced thrombocytopenia

Learn More About Dr. Cabral

Plumadore E, Lombardo L, Cabral KP. Pharmacotherapy Review: Expanding Treatment Modalities in Transthyretin Cardiac Amyloidosis. Am J Health Syst Pharm 2022;79:52-62.

Padala SK, Lavelle MP, Sidhu MS, Cabral KP, Morrone D, Boden WE, Toth PP. Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review. J Card Pharm Ther Nov 2017;22(6):499-510.

Boden WE, Padala SK, Cabral KP, Buschmann I, Sidhu MS. The Role of Short-Acting Nitroglycerin in the Management of Ischemic Heart Disease. Drug Design, Development and Therapy 2015; 9:4793-4805.

Cabral KP, Ansell JE. The Role of Factor Xa Inhibitors in VTE Treatment. Vasc Health Risk Manag Jan 2015; 11:117-123.

Cabral KP. Pharmacology for the New Target-Specific Oral Anticoagulants. J Thromb Thrombolysis 2013; 36(2):133-140.

Garrison GD, Bidell M, Cabral K, Silvestro L, Boire A, Strang AF. Interdisciplinary Formative Assessments to Foster Student Learning in the Dual-Campus Large Classroom Setting (School Poster). AACP Annual Meeting, Boston MA, July 21-23, 2018.

Decina L, Parsels K, Cabral K. The Implementation of Pharmacy Consult Services in Lipid Management with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. NYS American College of Clinical Pharmacy Meeting, November 2, 2018.